Allergy Therapeutics PLC: Business Overview, Financials & Competitive Analysis
Allergy Therapeutics PLC scores 6/10 on the AskCyborg Cyborg Score (Solid). Specialized allergy immunotherapy player with differentiated technology and European market dominance, though facing typical growth-stage biotech pressures requiring successful pipeline advancement and market expansion. Allergy Therapeutics demonstrates solid fundamentals as a specialized biotech player with established commercial products, growing revenue (~£71.2M TTM), and meaningful pipeline progress. However, operational challenges.
What is Allergy Therapeutics PLC's industry? Allergy Therapeutics PLC (allergytherapeutics.com) operates in Specialty Pharmaceuticals / Biotechnology - Immunotherapy. AskCyborg classifies Allergy Therapeutics PLC under Specialty Pharmaceuticals / Biotechnology - Immunotherapy in its company registry.
Allergy Therapeutics is a UK-based biotechnology company focused on developing and commercializing immunotherapies for allergic disorders. The company operates across nine European countries with a portfolio of inject...
Cyborg Score thesis
Specialized allergy immunotherapy player with differentiated technology and European market dominance, though facing typical...
Read the full analyst-debate transcript →Get the Latest Allergy Therapeutics PLC Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAllergy Therapeutics PLC Overview
Pro stress-test →Allergy Therapeutics is a UK-based biotechnology company focused on developing and commercializing immunotherapies for allergic disorders. The company operates across nine European countries with a portfolio of injectable and sublingual allergen-specific immunotherapies, targeting both established markets (Germany, Austria, Netherlands, Switzerland, Spain, Italy) and emerging opportunities.
Strategic Profile
Pro stress-test →The company combines commercial products like Pollinex Quattro and Oralvac with a promising R&D pipeline including Grass MATA MPL and VLP Peanut vaccine. Strategic positioning emphasizes aluminum-free immunotherapy technology with curative potential, supported by centralized UK manufacturing and R&D capabilities. Recent financing from Hayfin (£40m facility) and pursuit of Hong Kong listing indicate growth ambitions and geographic expansion strategy.
Competitive Landscape
Pro stress-test →Allergy Therapeutics competes in the specialized immunotherapy space against larger pharma entities like Stallergenes Greer and smaller regional players. The company's competitive advantage lies in aluminum-free formulations and established European distribution networks, but faces competition from emerging oral immunotherapy platforms and increasing interest from major pharma in allergy vaccines.
Industry Context
Allergy Therapeutics PLC operates in Specialty Pharmaceuticals / Biotechnology - Immunotherapy.
Key facts
Founded: 1998 · Headquarters: Worthing, UK · Employees: 584 · Revenue: £71.2m · Market cap: £706m (~$900m USD equiv.)